Phase II Study of Pembrolizumab (Keytruda®) in Advanced Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Feb 2017 Planned primary completion date changed from 1 Mar 2019 to 1 Apr 2018.
- 27 Apr 2016 Status changed from not yet recruiting to recruiting.
- 01 Feb 2016 New trial record